公开(公告)号：US20170145071A1

公开(公告)日：2017-05-25

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K45/06

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US20160185869A1

公开(公告)日：2016-06-30

申请号：US14976346

申请日：2015-12-21

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Robert Sikorski ,  Julie Hambleton ,  Neil Sankar

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

Abstract translation: 提供了结合集落刺激因子1受体（CSF1R）的抗体治疗色素沉着绒毛结节滑膜炎（PVNS）的方法。

公开(公告)号：US09173957B2

公开(公告)日：2015-11-03

申请号：US13905042

申请日：2013-05-29

Applicant: Five Prime Therapeutics, Inc.

Inventor： Lewis T. Williams ,  Elizabeth Bosch ,  Stephen K. Doberstein ,  Kevin Hestir ,  Diane Hollenbaugh ,  Ernestine Lee ,  Minmin Qin ,  Ali Sadra ,  Justin Wong ,  Ge Wu ,  Hongbing Zhang

IPC: A61K38/00 ,  A61K38/18 ,  A61K39/00 ,  C07K14/71 ,  C07K14/765 ,  A61K47/48 ,  C07K16/28 ,  C07K17/08 ,  A61K45/06

CPC classification number: C07K14/71 ,  A61K45/06 ,  C07K14/765 ,  C07K16/2863 ,  C07K17/08 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract translation: 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

公开(公告)号：US09169313B2

公开(公告)日：2015-10-27

申请号：US14079742

申请日：2013-11-14

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  W. Michael Kavanaugh

IPC: A61K39/00 ,  A61K38/18 ,  C07K14/475 ,  C07K14/50 ,  C07K14/71 ,  A61K38/17

CPC classification number: C07K14/71 ,  A61K38/179 ,  A61K38/1825

Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Abstract translation: 本发明涉及成纤维细胞生长因子受体I（FGFR1）细胞外结构域（EGFR）多肽用于治疗以成纤维细胞生长因子受体2（FGFR2）中配体依赖性激活突变为特征的癌症的用途。 例如，本发明涉及治疗子宫内膜癌和其它癌症，其中肿瘤细胞在蛋白质的IgII-IgIII铰链区或IgIII结构域中表达FGFR2突变体，例如在氨基酸位置252和/或253。

公开(公告)号：US20140170145A1

公开(公告)日：2014-06-19

申请号：US14048834

申请日：2013-10-08

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Dirk Behrens ,  Elizabeth Bosch ,  Stephen K. Doberstein ,  Robert Forgan Halenbeck ,  Kevin Hestir ,  Min Mei Huang ,  Ernestine Lee ,  Haishan Lin ,  Thomas Linnemann ,  Shannon Marshall ,  Justin Wong ,  Ge Wu ,  Aileen Zhou ,  Cindy Leo ,  Lewis T. Williams

IPC: C07K16/24

CPC classification number: C07K16/243 ,  A61K38/00 ,  C07K14/53

Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Abstract translation: 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。

公开(公告)号：US20140079699A1

公开(公告)日：2014-03-20

申请号：US14014446

申请日：2013-08-30

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92 ,  G01N2333/52 ,  G01N2333/96494 ,  G01N2800/52

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract translation: 提供了降低细胞因子水平的方法和用克隆集落刺激因子1受体（CSF1R）的抗体治疗病症的方法。 这些方法包括但不限于治疗炎症性疾病如风湿性关节炎的方法。

公开(公告)号：US20140056891A1

公开(公告)日：2014-02-27

申请号：US13913292

申请日：2013-06-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Harold KEER

IPC: A61K39/395 ,  A61K45/06 ,  A61K38/17

CPC classification number: C07K16/22 ,  A61K38/179 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

Abstract translation: 本发明提供了治疗患有癌症的患者的方法，包括向患者施用可溶性成纤维细胞生长因子受体1（FGFR1）融合蛋白，例如与Fc多肽或另一融合配偶体连接的FGFR1多肽的细胞外结构域。 融合蛋白可以以至少约2mg / kg体重的剂量施用。 在一些实施方案中，患者具有至少6pg / ml的成纤维细胞生长因子-2（FGF-2）血浆浓度。 在一些实施方案中，癌症的特征在于具有配体依赖性激活突变的成纤维细胞生长因子受体2（FGFR2）。

公开(公告)号：US20130324701A1

公开(公告)日：2013-12-05

申请号：US13905042

申请日：2013-05-29

Applicant: Five Prime Therapeutics, Inc.

Inventor： Lewis T. WILLIAMS ,  Elizabeth BOSCH ,  Stephen K. DOBERSTEIN ,  Kevin HESTIR ,  Diane HOLLENBAUGH ,  Ernestine LEE ,  Minmin QIN QIN ,  Ali SADRA ,  Justin WONG ,  Ge WU ,  Hongbing ZHANG ZHANG

IPC: C07K14/71 ,  C07K14/765 ,  C07K17/08 ,  C07K16/28

CPC classification number: C07K14/71 ,  A61K45/06 ,  C07K14/765 ,  C07K16/2863 ,  C07K17/08 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract translation: 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。